GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (NAS:GH) » Definitions » Revenue

GH (Guardant Health) Revenue : $692.3 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Guardant Health Revenue?

Guardant Health's revenue for the three months ended in Sep. 2024 was $191.5 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $692.3 Mil. Guardant Health's Revenue per Share for the three months ended in Sep. 2024 was $1.56. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $5.70.

During the past 12 months, the average Revenue per Share Growth Rate of Guardant Health was 14.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 19.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 14.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 8 years, Guardant Health's highest 3-Year average Revenue per Share Growth Rate was 87.80% per year. The lowest was 7.40% per year. And the median was 23.00% per year.


Guardant Health Revenue Historical Data

The historical data trend for Guardant Health's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health Revenue Chart

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial 214.38 286.73 373.65 449.54 563.95

Guardant Health Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 143.03 155.05 168.49 177.24 191.48

Competitive Comparison of Guardant Health's Revenue

For the Diagnostics & Research subindustry, Guardant Health's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardant Health's Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Revenue distribution charts can be found below:

* The bar in red indicates where Guardant Health's Revenue falls into.



Guardant Health Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $692.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guardant Health  (NAS:GH) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Guardant Health Revenue Related Terms

Thank you for viewing the detailed overview of Guardant Health's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardant Health Business Description

Traded in Other Exchanges
Address
3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Executives
Meghan V. Joyce director THE BOSTON BEER COMPANY, INC., ONE DESIGN CENTER PL., STE. 850, BOSTON MA 02210
Kumud Kalia officer: Chief Information Officer 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Ines Dahne-steuber officer: Chief Operating Officer 3100 HANOVER STREET, PALO ALTO CA 94304
Darya Chudova officer: Chief Technology Officer 3100 HANOVER STREET, PALO ALTO CA 94304
Helmy Eltoukhy director, officer: Chief Executive Officer 2 BARRY LANE, ATHERTON CA 94027
Amirali Talasaz director, officer: Chairman, President and COO 18 ISABELLA AVENUE, ATHERTON CA 94027
Musa Tariq director 3100 HANOVER STREET, PALO ALTO CA 94304
Amelia Merrill officer: SVP, People 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Steve E. Krognes director 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Stanley J Meresman director 2071 HUNTINGTON LANE, LOS ALTOS CA 94024
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Chris Freeman officer: Chief Commercial Officer 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Vijaya Gadde director C/O TWITTER INC, 1355 MARKET STREET SUITE 900, SAN FRANCISCO CA 94103
Bahija Jallal director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204